Pacira Pharmaceuticals (NASDAQ: PCRX) and Juniper Pharmaceuticals (NASDAQ:JNP) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, dividends, earnings, valuation, profitability, risk and institutional ownership.
Volatility and Risk
Pacira Pharmaceuticals has a beta of 1.95, meaning that its stock price is 95% more volatile than the S&P 500. Comparatively, Juniper Pharmaceuticals has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.
This is a breakdown of current ratings for Pacira Pharmaceuticals and Juniper Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Pacira Pharmaceuticals presently has a consensus target price of $45.50, indicating a potential upside of 42.63%. Juniper Pharmaceuticals has a consensus target price of $29.00, indicating a potential upside of 211.83%. Given Juniper Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Juniper Pharmaceuticals is more favorable than Pacira Pharmaceuticals.
Earnings and Valuation
This table compares Pacira Pharmaceuticals and Juniper Pharmaceuticals’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Pacira Pharmaceuticals||$286.63 million||4.53||-$42.61 million||($1.09)||-29.27|
|Juniper Pharmaceuticals||$49.98 million||2.02||$5.95 million||$0.60||15.50|
Juniper Pharmaceuticals has lower revenue, but higher earnings than Pacira Pharmaceuticals. Pacira Pharmaceuticals is trading at a lower price-to-earnings ratio than Juniper Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This table compares Pacira Pharmaceuticals and Juniper Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
39.7% of Juniper Pharmaceuticals shares are held by institutional investors. 6.6% of Pacira Pharmaceuticals shares are held by insiders. Comparatively, 11.6% of Juniper Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Juniper Pharmaceuticals beats Pacira Pharmaceuticals on 10 of the 14 factors compared between the two stocks.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company’s other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA). DepoCyt(e) is indicated for the intrathecal treatment of lymphomatous meningitis.
About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc. is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product. The service segment includes product development, clinical trial manufacturing, and advanced analytical and consulting services, as well as characterizing and developing its pharmaceutical product candidates. The Company’s pipeline of proprietary products includes JNP-0101, JNP-0201 and JNP-0301. JNP-0101 is developed to deliver oxybutynin for the treatment of overactive bladder in women. JNP-0201 is being designed to deliver natural hormones locally to vaginal tissue. JNP-0301 is being developed for the prevention of pre-term birth in women with a short cervical length. CRINONE is developed as a progesterone gel.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.